| abstract |
REFERS TO A COMPOUND OF FORMULAS (a), (b), AMONG OTHERS, WHERE R1 IS C1-C12 ALKYL, C2-C12 ALKINYL, C2-C12 ALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: [3 - ({[4- (1H-PYRAZOL-1-IL) BENZYL] (PYRIDIN-3-ILSULFONYL) AMINO} METHYL) -PHENOXY] ISOPROPYL ACETATE; ISOPROPYL 5- (3 - {[3- (3,5-DICLOFENOXY) PROPYL] - (METHYLSULFONIL) AMINO} -PROPYL) THIOPHENE-2-CARBOXYLATE, 3- (3 - {[(FENYLSULFONIL) - (4-PYRIDIN -3-ILBENCIL) -AMINO] METHYL} PHENYL) -TERC-BUTYL-PROPANOATE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. THE DESCRIBED COMPOUNDS ARE ESTERS AGONISTS OF THE EP2 RECEPTOR, USEFUL IN THE TREATMENT OF GLAUCOMA |